Vestal Point Capital Reports 8.3% Stake in Bicara Therapeutics Inc. (BCAX)

Vestal Point Capital, LP, along with Mr. Ryan Wilder, filed a Schedule 13G/A on May 15, 2026, disclosing an 8.3% stake in Bicara Therapeutics Inc. (BCAX). The reporting persons beneficially own 5,425,000 shares of common stock, which were acquired in the ordinary course of business. This filing represents a significant increase from a previously reported 0.0% position, marking a new substantial holding for the investment manager. The shares are held directly by a fund and a managed account for which Vestal Point Capital, LP serves as the investment adviser. Mr. Ryan Wilder, as the Chief Investment Officer and Managing Partner of the Investment Manager, shares voting and dispositive power over these securities. The calculation of the ownership percentage is based on 65,467,187 shares of common stock outstanding as of March 24, 2026. The filing indicates that the acquisition was not intended to influence or change the control of the issuer.